Corteva (CTVA) Q4 FY25 earnings call: guidance and Q&A

Clarification on how the Bayer agreement accelerates various technologies (triple-stack, insect resistance, cotton) and if it impacts E3/Conkesta or includes gene editing assumptions.

The agreement provides freedom to operate and increased access to the licensing market, accelerating corn licensing to 2027 (5 years earlier) and enabling entry into cotton licensing. It also brings the third-gen above-ground product forward by 2 years. The agreement resolves all outstanding litigation with Bayer and is expected to generate $1 billion in licensing income over the next decade. It does not directly accelerate E3/Conkesta but provides freedom to operate in canola and allows for streamlining R&D lines. Gene editing assumptions are not directly part of this agreement but are a separate growth vector.

“this is a comprehensive agreement. We've been working with Bayer for quite some time. These things are very scientifically based. They're very -- there's a lot of legal precedent here for us to work through. But I'd say what the agreement does is it provides 2 broad things. The first is we now have freedom to operate and an increased access to the licensing market, which is extremely important to us.”

asked by Christopher Parkinson · answered by Charles Magro

Whether the $610 million payment eliminates existing licensing expenses and if future use of HT4 would incur per-acre royalties or is covered by the upfront payment.

A portion of the $120 million net royalty benefit in the 2026 guide is due to not paying certain Bayer royalties, accelerating royalty neutrality by 2 years. The broader financial benefits of the agreement (over $100 million/year) are expected post-2027, focusing on offensive licensing income. Access to HT4 is not royalty-free; future use would incur royalties, similar to reciprocal licensing arrangements.

“in our current guide, we have $120 million of net royalty benefit in '26. A portion of that is the fact that there were some Bayer royalties that we will not be paying now in '26 and '27, so that's what accelerated us to a net neutral position in '26, which is 2 years ahead.”

asked by Vincent Andrews · answered by David Johnson

Reconciliation of the new royalty chart (showing $1 billion by 2035) with previous Investor Day charts, given statements of accelerated timelines.

The acceleration from the Bayer agreement is significant and should not appear the same as previous Investor Day charts. The agreement pulls corn licensing years ahead (starting 2027) and opens up cotton, which was not contemplated in earlier plans. The $1 billion target by 2035 is a new figure that includes these accelerations and new market entries, and does not yet contemplate hybrid wheat opportunities. The agreement puts the licensing business in a much higher gear.

“The acceleration that this agreement gives us is pretty powerful. When we were thinking about our original royalty journey, we were really talking about soybeans and then corn starting in late next decade. And now we're talking about corn starting now, basically in 2027, and then the introduction of cotton now.”

asked by Joel Jackson · answered by Charles Magro

Expectations for Europe's gene-edited seed framework in 2026 and its long-term impact, plus an update on the multi-disease resistant (MDR) corn product for the US market.

Corteva expects formal adoption of the EU gene-editing framework soon, likely by H1 2026, which is seen as science-based and practical, allowing for faster product introduction and improved food security. China approval is still needed. The gene-edited fungal disease-resistant corn hybrid (MDR) continues to look fantastic in test plots and is expected to be commercialized in the US within 1-2 years after regulatory approvals, with global expansion to follow.

“To your question with the EU, in December, there was an agreement with the EU framework. It still needs to be formally adopted by parliament and the council, and we are expecting that, hopefully, soon, I'd say, by the first half of this year. And we are very supportive of what we've seen so far.”

asked by Kevin McCarthy · answered by Charles Magro

Inquiry about the sustainability of strong FY25 free cash flow and expectations for 2026 conversion, including any one-off impacts.

FY25 free cash flow benefited from a favorable cash credit mix and strong working capital management, with net working capital as a percentage of sales 300-400 bps lower than typical. For 2026, absent one-time items, free cash flow conversion is expected to be in the 45%-50% range articulated at Investor Day, which is a few points lower than FY25 due to working capital normalizing. However, 2026 will be impacted by the Bayer agreement payment and separation costs, which will be shown as unusual items.

“When you look at the really -- the major portion of why we were favorable is our working capital management. And where we ended this particular year was down probably 300 to 400 basis points lower than typical in our net working capital as a percentage of sales.”

asked by Joshua Spector · answered by David Johnson

Explanation for the unusually high Q4 SG&A and R&D expenses, and an update on Conkesta soybeans' share and revenue expectations in Brazil.

The increase in R&D reflects a full-year build-up to over 8% of sales, not a Q4 specific timing issue. Q4 SG&A was impacted by higher variable compensation expenses, which were more impactful against a smaller revenue base. For Conkesta E3 in Brazil, Corteva expects to finish 2025 in mid-single-digit share and double or more than double that to mid-teens plus for 2026, transitioning to a 100% licensing model through multipliers. This transition contributes significantly to Seed's overall earnings growth in Brazil.

“On SG&A, as we mentioned in the opening comments, we do have some additional compensation expense, variable compensation expenses sort of items that hit in Q4, also hit in other quarters, but it was probably a little bit more impactful in Q4, especially against the small revenue number.”

asked by Jeff Zekauskas · answered by Charles Magro

Whether current channel inventory supports normalized purchasing in LatAm CP, or if volatility will continue, and the status of farmer credit/liquidity concerns in the region.

The LatAm CP market is expected to see continued pricing pressures in 2026 due to ample supply, but volume growth is anticipated as more land goes into production and pest/resistance pressures build. Channel inventories are currently about normal. Farmers in LatAm are stressed by high interest rates and suppressed commodity prices, leading to tight cash flow. Corteva is mitigating this through programs like its barter program, which will be near $1 billion in revenue this year, helping manage risk with farmers.

“Farmers in Latin America are stressed, very high interest rates, commodity price is a little bit suppressed, but they're still making money by and large. Cash flow is tight for them. And we've been working through a lot of those things with them.”

asked by Patrick Cunningham · answered by Robert King